Brief: Alligator Bioscience To Focus On HLX22 Project, Carry Out Rights Issue
BRIEF-Alligator Bioscience To Focus On HLX22 Project, Carry Out Rights Issue July 23 (Reuters) - Alligator Bioscience AB ATORX.ST:
DISCONTINUES INDEPENDENT DEVELOPMENT OF MITAZALIMAB FOR A STRATEGIC REFOCUS ON HLX22 PROJECT
DECISION FOLLOWS A REASSESSMENT OF THE PANCREATIC CANCER MARKET, WHERE RECENT ADVANCES IN TARGETED THERAPIES ARE EXPECTED TO RESHAPE THE COMPETITIVE LANDSCAPE
ANNOUNCES RIGHTS ISSUE OF SEK 125.6 MILLION SUBJECT TO EGM APPROVAL ON 26 AUG 2026
RIGHTS ISSUE COVERED TO SEK 58.8 MILLION BY UNDERTAKINGS AND GUARANTEES, 47% OF TOTAL
ENTERS BRIDGE LOAN AGREEMENTS TOTALING SEK 19 MILLION TO SECURE LIQUIDITY
INTENDS TO WIND DOWN ITS REMAINING ACTIVITIES, REDUCE ITS ORGANIZATION TO MINIMIZE GENERAL OPERATING COSTS
INTENDS TO SEEK TO OUT-LICENSE OR DIVEST MITAZALIMAB
Source text: ID:nMFN6R8mNg
Further company coverage: ATORX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Alligator Bioscience AB
See all newsSweden's Alligator Bioscience Q3 sales fall as R&D winds down
Brief: Alligator Bioscience Q3 EBIT SEK -19.3 Million
Brief: Alligator Bioscience Appoints Johan Gileus As CEO
Brief: Alligator Bioscience Announces Final Outcome In Rights Issue
Brief: Alligator Bioscience To Initially Receive SEK 58.8 Mln From Rights Issue